These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33760035)

  • 1. Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study.
    Horace RW; Roberts M; Shireman TI; Merhi B; Jacques P; Bostom AG; Liu S; Eaton CB
    Nephrol Dial Transplant; 2022 Jan; 37(2):382-389. PubMed ID: 33760035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
    Merhi B; Shireman T; Carpenter MA; Kusek JW; Jacques P; Pfeffer M; Rao M; Foster MC; Kim SJ; Pesavento TE; Smith SR; Kew CE; House AA; Gohh R; Weiner DE; Levey AS; Ix JH; Bostom A
    Am J Kidney Dis; 2017 Sep; 70(3):377-385. PubMed ID: 28579423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Dad T; Tighiouart H; Joseph A; Bostom A; Carpenter M; Hunsicker L; Kusek JW; Pfeffer M; Levey AS; Weiner DE
    Am J Kidney Dis; 2016 Aug; 68(2):277-286. PubMed ID: 26947217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients.
    Bostom A; Pasch A; Madsen T; Roberts MB; Franceschini N; Steubl D; Garimella PS; Ix JH; Tuttle KR; Ivanova A; Shireman T; Gohh R; Merhi B; Jarolim P; Kusek JW; Pfeffer MA; Liu S; Eaton CB
    Am J Nephrol; 2018; 48(1):21-31. PubMed ID: 29996127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Angiopoietins in Cardiovascular Outcomes of Kidney Transplant Recipients: An Ancillary Study from the FAVORIT.
    Gendy N; Brown L; Staunton MK; Garg K; Hernandez Garcilazo N; Qian L; Yamamoto Y; Ugwuowo U; Obeid W; Al-Qusairi L; Bostom A; Mansour SG
    Am J Nephrol; 2024; 55(5):597-606. PubMed ID: 38735283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
    Weiner DE; Park M; Tighiouart H; Joseph AA; Carpenter MA; Goyal N; House AA; Hsu CY; Ix JH; Jacques PF; Kew CE; Kim SJ; Kusek JW; Pesavento TE; Pfeffer MA; Smith SR; Weir MR; Levey AS; Bostom AG
    Am J Kidney Dis; 2019 Jan; 73(1):51-61. PubMed ID: 30037726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
    Kalil RS; Carpenter MA; Ivanova A; Gravens-Mueller L; John AA; Weir MR; Pesavento T; Bostom AG; Pfeffer MA; Hunsicker LG
    Am J Kidney Dis; 2017 Dec; 70(6):762-769. PubMed ID: 28801121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients.
    Kang AW; Bostom AG; Kim H; Eaton CB; Gohh R; Kusek JW; Pfeffer MA; Risica PM; Garber CE
    Nephrol Dial Transplant; 2020 Aug; 35(8):1436-1443. PubMed ID: 32437569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
    Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial.
    Malhotra R; Katz R; Weiner DE; Levey AS; Cheung AK; Bostom AG; Ix JH
    Am J Hypertens; 2019 Aug; 32(9):816-823. PubMed ID: 31179500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High diet quality indices associated with lower risk of lipid profile abnormalities in Taiwanese kidney transplant recipients.
    Lin IH; Van Duong T; Nien SW; Tseng IH; Wu YM; Chiang YJ; Wang HH; Chiang CY; Wang MH; Chiu CH; Lin YT; Wong TC
    Sci Rep; 2023 Nov; 13(1):19662. PubMed ID: 37952063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.
    Weiner DE; Carpenter MA; Levey AS; Ivanova A; Cole EH; Hunsicker L; Kasiske BL; Kim SJ; Kusek JW; Bostom AG
    Am J Transplant; 2012 Sep; 12(9):2437-45. PubMed ID: 22594581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Differences in Medication Utilization for Secondary Prevention of Cardiovascular Disease in Kidney Transplant Recipients: A Post Hoc Analysis of the FAVORIT Trial Cohort.
    Fallahzadeh MK; Ku E; Chu CD; McCulloch CE; Tuot DS
    Kidney Med; 2022 Apr; 4(4):100438. PubMed ID: 35360084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remnant cholesterol as a risk factor for all-cause and cardiovascular mortality in incident peritoneal dialysis patients.
    Deng J; Tang R; Chen J; Zhou Q; Zhan X; Long H; Peng F; Wang X; Wen Y; Feng X; Su N; Tang X; Tian N; Wu X; Xu Q
    Nutr Metab Cardiovasc Dis; 2023 May; 33(5):1049-1056. PubMed ID: 36948938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in kidney transplant recipients: Japan Academic Consortium of Kidney Transplantation (JACK) cohort study.
    Okumi M; Kakuta Y; Unagami K; Maenosono R; Miyake K; Iizuka J; Takagi T; Ishida H; Tanabe K;
    Clin Exp Nephrol; 2018 Jun; 22(3):702-709. PubMed ID: 29159526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol.
    Pita-Fernández S; Pértega-Díaz S; Valdés-Cañedo F; Seijo-Bestilleiro R; Seoane-Pillado T; Fernández-Rivera C; Alonso-Hernández A; Lorenzo-Aguiar D; López-Calvino B; López-Muñiz A
    BMC Cardiovasc Disord; 2011 Jan; 11():2. PubMed ID: 21639867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure.
    Bostom A; Steubl D; Garimella PS; Franceschini N; Roberts MB; Pasch A; Ix JH; Tuttle KR; Ivanova A; Shireman T; Kim SJ; Gohh R; Weiner DE; Levey AS; Hsu CY; Kusek JW; Eaton CB
    Am J Nephrol; 2018; 47(4):275-282. PubMed ID: 29698955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
    Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
    Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher mortality risk among kidney transplant recipients than among estimated glomerular filtration rate-matched patients with CKD-preliminary results.
    Cheddani L; Liabeuf S; Essig M; Snanoudj R; Jacquelinet C; Kerleau C; Metzger M; Balkau B; Drüeke TB; Hourmant M; Massy ZA;
    Nephrol Dial Transplant; 2021 Jan; 36(1):176-184. PubMed ID: 32162656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Aortic Calcification, Cardiovascular Events, and Mortality in Kidney and Pancreas-Kidney Transplant Recipients.
    Lewis JR; Wong G; Taverniti A; Vucak-Dzumhur M; Elder GJ
    Am J Nephrol; 2019; 50(3):177-186. PubMed ID: 31394536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.